209 related articles for article (PubMed ID: 19354288)
1. Ribonuclease inhibitor regulates neovascularization by human angiogenin.
Dickson KA; Kang DK; Kwon YS; Kim JC; Leland PA; Kim BM; Chang SI; Raines RT
Biochemistry; 2009 May; 48(18):3804-6. PubMed ID: 19354288
[TBL] [Abstract][Full Text] [Related]
2. Crystal structures of murine angiogenin-2 and -3-probing 'structure--function' relationships amongst angiogenin homologues.
Iyer S; Holloway DE; Acharya KR
FEBS J; 2013 Jan; 280(1):302-18. PubMed ID: 23170778
[TBL] [Abstract][Full Text] [Related]
3. Refined crystal structures of native human angiogenin and two active site variants: implications for the unique functional properties of an enzyme involved in neovascularisation during tumour growth.
Leonidas DD; Shapiro R; Allen SC; Subbarao GV; Veluraja K; Acharya KR
J Mol Biol; 1999 Jan; 285(3):1209-33. PubMed ID: 9918722
[TBL] [Abstract][Full Text] [Related]
4. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
[TBL] [Abstract][Full Text] [Related]
5. Site-specific mutagenesis reveals differences in the structural bases for tight binding of RNase inhibitor to angiogenin and RNase A.
Chen CZ; Shapiro R
Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1761-6. PubMed ID: 9050852
[TBL] [Abstract][Full Text] [Related]
6. Molecular recognition of human angiogenin by placental ribonuclease inhibitor--an X-ray crystallographic study at 2.0 A resolution.
Papageorgiou AC; Shapiro R; Acharya KR
EMBO J; 1997 Sep; 16(17):5162-77. PubMed ID: 9311977
[TBL] [Abstract][Full Text] [Related]
7. Replacing a surface loop endows ribonuclease A with angiogenic activity.
Raines RT; Toscano MP; Nierengarten DM; Ha JH; Auerbach R
J Biol Chem; 1995 Jul; 270(29):17180-4. PubMed ID: 7615514
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of loss of functions of human angiogenin variants implicated in amyotrophic lateral sclerosis.
Padhi AK; Kumar H; Vasaikar SV; Jayaram B; Gomes J
PLoS One; 2012; 7(2):e32479. PubMed ID: 22384259
[TBL] [Abstract][Full Text] [Related]
9. High-resolution crystal structures of ribonuclease A complexed with adenylic and uridylic nucleotide inhibitors. Implications for structure-based design of ribonucleolytic inhibitors.
Leonidas DD; Chavali GB; Oikonomakos NG; Chrysina ED; Kosmopoulou MN; Vlassi M; Frankling C; Acharya KR
Protein Sci; 2003 Nov; 12(11):2559-74. PubMed ID: 14573867
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the interactions of human ribonuclease inhibitor with angiogenin and ribonuclease A by mutagenesis: importance of inhibitor residues inside versus outside the C-terminal "hot spot".
Shapiro R; Ruiz-Gutierrez M; Chen CZ
J Mol Biol; 2000 Sep; 302(2):497-519. PubMed ID: 10970748
[TBL] [Abstract][Full Text] [Related]
11. Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity.
Rutkoski TJ; Raines RT
Curr Pharm Biotechnol; 2008 Jun; 9(3):185-9. PubMed ID: 18673284
[TBL] [Abstract][Full Text] [Related]
12. Unexpected binding mode for 2'-phosphoadenosine-based nucleotide inhibitors in complex with human angiogenin revealed by heteronuclear NMR spectroscopy.
Tonan K; Xu P; Jenkins JL; Russo A; Shapiro R; Ni F
Biochemistry; 2003 Sep; 42(38):11137-49. PubMed ID: 14503864
[TBL] [Abstract][Full Text] [Related]
13. Human placental ribonuclease inhibitor abolishes both angiogenic and ribonucleolytic activities of angiogenin.
Shapiro R; Vallee BL
Proc Natl Acad Sci U S A; 1987 Apr; 84(8):2238-41. PubMed ID: 3470787
[TBL] [Abstract][Full Text] [Related]
14. Ribonuclease A variants with potent cytotoxic activity.
Leland PA; Schultz LW; Kim BM; Raines RT
Proc Natl Acad Sci U S A; 1998 Sep; 95(18):10407-12. PubMed ID: 9724716
[TBL] [Abstract][Full Text] [Related]
15. High-level soluble production and characterization of porcine ribonuclease inhibitor.
Klink TA; Vicentini AM; Hofsteenge J; Raines RT
Protein Expr Purif; 2001 Jul; 22(2):174-9. PubMed ID: 11437592
[TBL] [Abstract][Full Text] [Related]
16. Selective abolition of pancreatic RNase binding to its inhibitor protein.
Kumar K; Brady M; Shapiro R
Proc Natl Acad Sci U S A; 2004 Jan; 101(1):53-8. PubMed ID: 14681553
[TBL] [Abstract][Full Text] [Related]
17. Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains.
Newton DL; Xue Y; Olson KA; Fett JW; Rybak SM
Biochemistry; 1996 Jan; 35(2):545-53. PubMed ID: 8555226
[TBL] [Abstract][Full Text] [Related]
18. Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity.
Boix E; Wu Y; Vasandani VM; Saxena SK; Ardelt W; Ladner J; Youle RJ
J Mol Biol; 1996 Apr; 257(5):992-1007. PubMed ID: 8632481
[TBL] [Abstract][Full Text] [Related]
19. A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity.
Kao RY; Jenkins JL; Olson KA; Key ME; Fett JW; Shapiro R
Proc Natl Acad Sci U S A; 2002 Jul; 99(15):10066-71. PubMed ID: 12118120
[TBL] [Abstract][Full Text] [Related]
20. Engineered human angiogenin mutations in the placental ribonuclease inhibitor complex for anticancer therapy: Insights from enhanced sampling simulations.
Cong X; Cremer C; Nachreiner T; Barth S; Carloni P
Protein Sci; 2016 Aug; 25(8):1451-60. PubMed ID: 27110669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]